Galmed Pharma (GLMD) Misses Q4 EPS by 5c

Galmed Pharma (NASDAQ: GLMD) reported Q4 EPS of ($0.39), $0.05 worse than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AeroVironment restates quarterly financials, citing $89M goodwill error
• Galmed completes Colospan acquisition under restructured terms